FD-AID Periodic Regulatory Intelligence Report

CDER Warning Letter Trends: 2024–September 2026

FDA Warning Letters reveal where enforcement attention is being directed, which compliance failures continue to recur, and where pharmaceutical companies may be underestimating their regulatory exposure.

Prepared by FD-AID, LLC, this report evaluates Warning Letters identified in FDA’s public database as issued by the Center for Drug Evaluation and Research (CDER). It compares enforcement activity during 2024, 2025, and 2026 through September 19, while distinguishing broad enforcement campaigns from Warning Letters involving pharmaceutical manufacturing and cGMP compliance.

The report examines:

• Changes in CDER Warning Letter volume
• Geographic enforcement patterns
• Frequently cited cGMP deficiencies
• Quality-system weaknesses appearing across multiple firms
• Risks involving investigations, laboratory controls, data integrity, supplier oversight, and Quality Unit responsibilities
• Practical actions companies can take to reduce regulatory risk and improve inspection readiness

This is more than a compilation of Warning Letters. The report converts FDA enforcement activity into actionable regulatory intelligence, helping Quality, Regulatory Affairs, Compliance, and executive leadership identify patterns before those same deficiencies appear during an FDA inspection.

The report was prepared by DeVaughn Edwards, founder of FD-AID, LLC and a former FDA Investigator with 14 years of agency experience inspecting pharmaceutical and biotechnology operations in more than 20 countries.

Format: Downloadable PDF

Edition: Version 1.1, independently reviewed

Data cutoff: September 19, 2026

This report is intended for pharmaceutical executives, Quality Unit personnel, regulatory professionals, consultants, auditors, and organizations preparing for FDA inspection.